Literature DB >> 26475730

A novel 3D high-content assay identifies compounds that prevent fibroblast invasion into tissue surrogates.

Carsten Wenzel1, Saskia Otto1, Stefan Prechtl1, Karsten Parczyk1, Patrick Steigemann2.   

Abstract

Invasion processes underlie or accompany several pathological processes but only a limited number of high-throughput capable phenotypic models exist to test anti-invasive compounds in vitro. We here evaluated 3D co-cultures as a high-content phenotypic screening system for fibrotic invasive processes. 3D multicellular spheroids were used as living tissue surrogates in co-culture with fluorescently labeled lung fibroblasts to monitor invasion processes by automated microscopy. This setup was used to screen a compound library containing 480 known bioactive substances. Identified hits prevented fibroblast invasion and could be subdivided into two hit classes. First, Prostaglandins were shown to prevent fibroblast invasion, most likely mediated by the prostaglandin EP2 receptor and generation of cAMP. Additionally, Rho-associated protein kinase (ROCK) inhibitors prevented fibroblast invasion, possibly by inactivation of myosin II. Importantly, both Prostaglandins and ROCK inhibitors are potential treatment options shown to be effective in in vitro and in vivo models of fibrotic diseases. This validates the presented novel phenotypic screening approach for the evaluation of potential inhibitors and the identification of novel compounds with activity in diseases that are associated with fibroblast invasion.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D co-culture; Fibroblast invasion; High-content invasion assay; Living tissue surrogate; Prostaglandin; ROCK

Mesh:

Substances:

Year:  2015        PMID: 26475730     DOI: 10.1016/j.yexcr.2015.10.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

Review 1.  Screening out irrelevant cell-based models of disease.

Authors:  Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

Review 2.  Biofabrication of phenotypic pulmonary fibrosis assays.

Authors:  Cameron Yamanishi; Stephen Robinson; Shuichi Takayama
Journal:  Biofabrication       Date:  2019-06-19       Impact factor: 9.954

3.  Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model.

Authors:  Yeonhwa Song; Sanghwa Kim; Jinyeong Heo; David Shum; Su-Yeon Lee; Minji Lee; A-Ram Kim; Haeng Ran Seo
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

4.  High-Content Monitoring of Drug Effects in a 3D Spheroid Model.

Authors:  Frédérique Mittler; Patricia Obeïd; Anastasia V Rulina; Vincent Haguet; Xavier Gidrol; Maxim Y Balakirev
Journal:  Front Oncol       Date:  2017-12-11       Impact factor: 6.244

5.  Adaptation of the in vitro micronucleus assay for genotoxicity testing using 3D liver models supporting longer-term exposure durations.

Authors:  Gillian E Conway; Ume-Kulsoom Shah; Samantha Llewellyn; Tereza Cervena; Stephen J Evans; Abdullah S Al Ali; Gareth J Jenkins; Martin J D Clift; Shareen H Doak
Journal:  Mutagenesis       Date:  2020-09-12       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.